The Antibiotics for Children With Severe Diarrhoea (ABCD) trial project led by WHO is a multi-site randomized, double-bind, placebo-controlled clinical trial attempting to evaluate the ability of an antibiotic (azithromycin) in reducing mortality within 90 days of the acute diarrhoeal episode and improve nutritional status over the same period.Read More >
What We Do
The International Vaccine Access Center accelerates equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.
Our Approach Blends
- Rigorous science
- Productive partnership
- Clear communication
- Capacity building and training
Our Practice Areas
Based on demand from country leaders and health agencies around the world, we provide independent policy advice, support country vaccine decision-making and governance, and connect partners to accelerate progress toward health and development goals.
Coverage & Equity
To improve equitable immunization within and between countries, we help countries better measure vaccine coverage, interpret results for action, and boost demand for vaccination using novel strategies.
Major studies evaluate the feasibility of using blood samples to identify gaps in immunity and implement mobile-based reminder systems, two approaches that could be adopted by governments to strengthen vaccination programs and protect all children.
To inform and improve prevention and control strategies, we manage large clinical studies and surveillance networks. We also quantify the amount of disease in countries and globally via mathematical models constructed with an understanding of population-level epidemiology, health system, and policy contexts.
Economics & Finance
To support investment and funding decisions, we quantify the cost of illness from diseases and determine the economic return on investment of vaccine use. We also help countries identify and address financing and affordability challenges.
To inform policy & investments, we evaluate how vaccines reduce the spread of disease and create other value post introduction and over time.
To support the introduction of new vaccines and improvements in coverage, we analyze the programmatic and logistical implications of policy choices, such as variations in shipping, packaging, and other operational decisions that affect cost and health impact. Digital tools aid countries in designing, planning, and improving supply chains.
As a leading contributor to global immunization policy, we synthesize & present evidence to build consensus, inform strategy and support policy development. Members of IVAC’s leadership serve on the WHO Strategic Advisory Group of Experts (SAGE) and on several WHO working groups.
To advance evidence-based policy, we support technically driven efforts, led by global and in-country partners, to understand the value of vaccines. We develop compendiums of published evidence, formulate messaging, and develop advocacy materials. We also build and manage coalitions and networks of scientists and other health advocates.
BASIS is a partnership led by the Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center (IVAC), in collaboration with key Indian institutions, and is designed to establish a robust baseline estimate of pneumococcal serotype distribution prior to the introduction of PCV.Read More >
Effect of Age on Pneumococcal Vaccine Immunogenicity in Adults Over 50 Years of Age CHALLENGE Many high income countries recommend immunization with pneumococcal polysaccharide vaccine and/or pneumococcal conjugate vaccines for adults over 50 years of age. WHO guidance to countries globally regarding adult immunization in the context of widespread use of infant PCV programs is […]Read More >
Policy makers may be better able to evaluate the progress of measles elimination and rubella control programs by understanding population immunity through large-scale serological surveys. This is a collaborative study led by the Indian Council of Medical Research.Read More >
PCV Interchangeability Assessment CHALLENGE Three pneumococcal conjugate vaccine (PCV) products are currently World Health Organization (WHO)-prequalified and available for use worldwide. With multiple products available, countries will need to consider interchangeability issues, namely the ability to use more than one PCV product without adversely affecting the safety or the effectiveness of the PCV program. APPROACH […]Read More >